FDA Accepts Amended Protocol for Phase 3 Trial of Buntanetap in Alzheimer Disease
According to a new announcement, the FDA has accepted an updated protocol for Annovis Bio’s pivotal phase 3 AD study testing the therapeutic potential of its investigational agent buntanetap, an orally available small molecule.1 In October 2024, the …